The previously approved checkpoint inhibitors, monoclonal antibodies directed against the checkpoints CTLA‐4 and PD-1/PD-L1, are used in various tumor entities (including lung, kidney, and urothelial carcinoma; head and neck cancer; melanoma; and Hodgkin lymphoma). The gene discussed is CD274; the disease is neoplasm.